Bioretec Oy

Bioretec Oy EBIT Margin

The EBIT Margin (Operating Margin) of Bioretec Oy (BRETEC.HE) as of Nov 5, 2026 is -246.64 %. In the previous year, EBIT Margin (Operating Margin) was -92.48 % — a change of 166.70% (lower).

EBIT Margin

-246.64 %

YoY

166.70%

Last updated:

EBIT Margin (Operating Margin) of Bioretec Oy is 2025 -246.64 % . EBIT Margin (Operating Margin) of Bioretec Oy was 2024 -92.48 % . It decreases by 166.70% lower compared to the previous year.

Bioretec Oy's operating (EBIT) margin stands at -246.6%, down from -133.1% several years earlier.

The Bioretec Oy EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-101.07 EUR
Jan 1, 2019
-99.48 EUR
Jan 1, 2020
-128.39 EUR
Jan 1, 2021
-133.10 EUR
Jan 1, 2022
-77.90 EUR
Jan 1, 2023
-77.67 EUR
Jan 1, 2024
-92.48 EUR
Jan 1, 2025
-246.64 EUR
The Bioretec Oy EBIT Margin history
YEAREBIT MarginYoY
-246.64 %+166.70%
-92.48 %+19.07%
-77.67 %-0.29%
-77.90 %-41.48%
-133.10 %+3.67%
-128.39 %+29.05%
-99.48 %-1.56%
-101.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bioretec Oy Stock analysis

What does Bioretec Oy do? Bioretec Oy develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics, operating as a developer, manufacturer, and commercializer of innovative bioresorbable orthopedic implants and implant materials. The company's Activa product portfolio includes bioabsorbable biopolymer products available in the market for pediatric, trauma, and sports surgery applications. Bioretec Oy has a Germany-based subsidiary, BRI.Tech GmbH, and its products are used globally across various medical specialties. The company generates revenue through the sale of its Activa product portfolio, targeting healthcare providers and medical institutions worldwide. The Activa products are designed for bone and soft tissue injury treatments, serving segments in pediatrics, trauma surgery, and sports medicine. Bioretec Oy's global distribution network enables the commercialization of its implants in international markets. Bioretec Oy's business model focuses on the development, manufacturing, and commercialization of bioresorbable orthopedic solutions. The company's products are marketed under the Activa brand, catering to medical professionals in specialized surgical fields. The Germany-based subsidiary BRI.Tech GmbH supports the company's operations in the European market. Bioretec Oy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioretec Oy stock

EBIT Margin (Operating Margin) of Bioretec Oy is -246.64 % in 2025.

EBIT Margin (Operating Margin) of Bioretec Oy changed from -92.48 % to -246.64 %, representing a 166.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Bioretec Oy since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Bioretec Oy with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Bioretec Oy

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Bioretec Oy